GigaGen Profiled in Nature

San Francisco — GigaGen’s experience with the NCI/NIH Lean LaunchPad program has been highlighted in an article in Nature.


GigaGen Wins Slots in Highly Competitive Startup Accelerators

SAN FRANCISCO – GigaGen CEO David Johnson announced today that the company has won slots in two highly competitive startup accelerators: the BayBIO F.A.S.T. program, and the StartX accelerator. F.A.S.T. is a 10-week program that matches GigaGen with hundreds of biotech advisers from a variety of industries, such as contract manufacturing, clinical study design, and finance. F.A.S.T is sponsored by biotech companies interested to discover the best innovators of the Bay Area, including Johnson & Johnson, Bayer, and Amgen. StartX is an educational non-profit that accelerates the development of Stanford’s top entrepreneurs through experiential education and collective intelligence. GigaGen boasts Stanford graduates CEO David Johnson (PhD Genetics), COO Carter Keller (BS engineering), Director of R&D Adam Adler (PhD Cancer Bio), and Co-Founder Everett Meyer (Professor of Medicine; MD PhD). Fewer than 5% of applicants are accepted to the StartX program.



GigaGen Wins Grants from NCI for Antibody Technology

SAN FRANCISCO, CA – GigaGen has won two Phase I grants from the National Cancer Institute’s highly competitive SBIR program. These Phase I grants support improvements in GigaGen’s technology for high-throughput genetic analysis of primary B cells. One project involves improvements to GigaGen’s antibody protein expression technology. The second project involves improvements to GigaGen’s microfluidic chip technology, which will improve throughput tenfold over the current design. CEO Dr. Johnson is the Principal Investigator for both grants.

GigaGen Participates in Inaugural NIH I-Corps Commercialization Program

WASHINGTON DC – GigaGen Inc. participated in Steve Blank’s inaugural Lean LaunchPad for the National Cancer Institute at the National Institutes of Health. The Lean LaunchPad program has been profiled in Harvard Business Review, and is now a core part of entrepreneurship programs at business schools such as Stanford GSB and Berkeley-Haas School of Business. GigaGen interviewed a record 163 customers and stakeholders to assess the viability of their preclinical recombinant gammaglobulin product. As part of the program, GigaGen’s CEO traveled to Prague, Czech Republic, for the worldwide meeting of the European Society for Immune Deficiency, where he met with dozens of physicians, nurses, and patients. GigaGen also spoke with FDA, recombinant protein producers, plasma product companies, and the Immune Deficiency Foundation.



GigaGen Wins Grant for Immune Repertoire Sequencing Technology

SAN FRANCISCO, CA – GigaGen has won a Phase II Small Business Innovation Research (SBIR) grant for $950K from the National Cancer Institute (NCI). The funds will be used to develop and commercialize molecular kits for immune repertoire sequencing.

GigaGen Presents at the 2014 BIO International Convention

SAN DIEGO, CA – GigaGen CEO David Johnson traveled to San Diego to meet with dozens of potential collaborators at big pharma and smaller biotech companies. Dr. Johnson presented a poster describing GigaGen’s technology and opportunities for collaboration. GigaGen’s participation was generously supported by a grant from the National Science Foundation.

GigaGen Invents Novel Microfluidic Chip Geometry

SAN FRANCISCO, CA – GigaGen has invented a novel microfluidic chip geometry for water-in-oil microdroplet merging. The technology is particularly useful for applications that require lysis of a cell followed by dilution with PCR amplification reagents.